NCT05477095View on ClinicalTrials.gov

A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-313 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

July 6, 2022

Primary Completion Date

October 6, 2023

Study Completion Date

October 6, 2023

Conditions

Migraine

Interventions

BIOLOGICAL

UB-313

A synthetic peptide-based immunotherapy

BIOLOGICAL

Placebo

Normal saline

Trial Locations (1)

Unknown

Katholieke Universiteit Leuven, Leuven

All Listed Sponsors

lead

Vaxxinity, Inc.

INDUSTRY